Maria Mullikin, NP
Family · Cheyenne, WYNPI 1417226994
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.0% of the total across 67 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 25 manufacturers, the largest accounting for just 13.1% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $612 and has fallen 97.5% since, to $16 in 2025.
Across 67 payments — averaging $17.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$158
- AbbVie$118
- AstraZeneca$113
- Amgen$100
- Vanda Pharmaceuticals Inc.$98
- Boehringer Ingelheim$96
- plus $522 from 19 others
What the payments were for
- Food & beverage$1,19299%
- Education$121%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 10 | $158 |
| AbbVie | 5 | $118 |
| AstraZeneca | 6 | $113 |
| Amgen | 5 | $100 |
| Vanda Pharmaceuticals Inc. | 4 | $98 |
| Boehringer Ingelheim | 6 | $96 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $59 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 4 | $56 |
| Nestle Healthcare Nutrition Inc. | 3 | $48 |
| Merck | 3 | $46 |
| Daiichi Sankyo Inc. | 2 | $39 |
| Novo Nordisk | 2 | $36 |
| Inari Medical, Inc. | 1 | $34 |
| Lilly USA, LLC | 2 | $30 |
| Biohaven Pharmaceuticals, Inc. | 1 | $23 |
| Jazz Pharmaceuticals Inc. | 1 | $21 |
| Lundbeck LLC | 1 | $18 |
| Bayer | 1 | $18 |
| Ultragenyx Pharmaceutical Inc. | 1 | $16 |
| Eisai Inc. | 1 | $15 |
| Alkermes, Inc. | 1 | $14 |
| Biogen | 1 | $14 |
| Dexcom, Inc. | 1 | $13 |
| Impel Pharmaceuticals Inc. | 1 | $12 |
| Pfizer | 1 | $11 |
How this compares
$1,204 in reported general payments places this provider in the 80th percentile of 284 family providers in Wyoming.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Atorvastatin Calcium | 50 | $395 |
| Levothyroxine Sodium | 31 | $313 |
| Potassium Chloride | 13 | $143 |
| Simvastatin | 17 | $131 |
| Lisinopril | 20 | $95 |
| Pantoprazole Sodium | 12 | $83 |
| Metoprolol Succinate | 14 | $60 |
| Rosuvastatin Calcium | 11 | $12 |
Paid to pharmacies, not to this prescriber.
Other family in Cheyenne
- Jill GiranyCheyenne$44K
- Kathryn HeimerCheyenne$5K
- Greta SkagenCheyenne$4K
- Jennifer DavisCheyenne$4K
- Anne BarnesCheyenne$4K
- Katherine BrockCheyenne$3K
- Lana SykesCheyenne$3K
- Sheriedan GrannanCheyenne$3K
- Shala SwarmCheyenne$2K
- Heather RobertsCheyenne$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.